Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike
Zogenix shares are clawing back some of the value they lost 2 months ago after the FDA hit the biotech with a refuse-to-file notice …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
